Formycon AG (ETR:FYB)
29.90
+1.65 (5.84%)
Jun 26, 2025, 5:26 PM CET
Formycon AG Employees
Formycon AG had 250 employees as of December 31, 2024. The number of employees increased by 12 or 5.04% compared to the previous year.
Employees
250
Change (1Y)
12
Growth (1Y)
5.04%
Revenue / Employee
€278,696
Profits / Employee
€502,688
Market Cap
522.64M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Siemens Healthineers AG | 72,000 |
Merck KGaA | 59,020 |
Bayer Aktiengesellschaft | 91,864 |
Fresenius SE & Co. KGaA | 176,486 |
Fresenius Medical Care AG | 111,513 |
Sartorius Aktiengesellschaft | 13,528 |
Carl Zeiss Meditec AG | 5,730 |
Fielmann Group AG | 24,363 |
Formycon AG News
- 16 hours ago - EQS-News: Teva becomes secondary commercialization partner for Formycon's Stelara biosimilar FYB202 (ustekinumab) under the brand name Fymskina in Germany - Wallstreet:Online
- 1 day ago - EQS-News: U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/AHZANTIVE (aflibercept-mrbb) in the United States and Canada - Wallstreet:Online
- 2 days ago - EQS-News: Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period - Wallstreet:Online
- 6 days ago - EQS-News: Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse - Wallstreet:Online
- 8 days ago - EQS-News: Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities - Wallstreet:Online
- 8 days ago - EQS-News: Formycon AG: Subscription period for 2025/2029 corporate bond has started - Wallstreet:Online
- 9 days ago - EQS-News: Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets - Wallstreet:Online
- 9 days ago - EQS-Adhoc: Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth - Wallstreet:Online